Innovative Medicine worldwide operational sales grew 3.8%, with net acquisitions and divestitures positively impacting growth by 1.4%. Growth was primarily driven by DARZALEX, CARVYKTI, ERLEADA and RYBREVANT/LAZCLUZE in Oncology, TREMFYA and SIMPONI/SIMPONI ARIA in Immunology, and SPRAVATO in Neuroscience. Growth was partially offset by an approximate (1,170) basis points impact from STELARA in Immunology, and an approximate (130) basis points impact from COVID-19 in Infectious Diseases. MedTech worldwide operational sales grew 6.1%, with net acquisitions and divestitures positively impacting growth by 2.0%. Growth was primarily driven by electrophysiology products and Abiomed in Cardiovascular, as well as wound closure products in General Surgery.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson reports Q2 adjusted EPS $2.77, consensus $2.68
- Johnson & Johnson raises FY25 adjusted operational EPS view to $10.63-$10.73
- Is Johnson & Johnson (JNJ) a Good Stock to Buy before Earnings?
- Notable companies reporting before tomorrow’s open
- Options Volatility and Implied Earnings Moves This Week, July 15 – July 18, 2025